AbbVie to buy immune drug developer Landos

BioPharma Dive· Industry Dive
Delilah Alvarado
2 min read
0
In this article:

Dive Brief:

  • Abbvie is expanding its pipeline of inflammatory disease drugs, announcing Monday a small deal to acquire biotechnology company Landos Biopharma.

  • Per the deal, Abbvie will buy Landos for $20.42 per share, or about $138 million. Abbvie has also agreed to pay a so-called contingent value right worth $11.14 per share, or another $75 million, if certain milestones are met. The upfront price represents a premium of about 155% to the closing price Friday of Landos stock.

  • Landos is currently running a mid-stage trial of its lead drug, dubbed NX-13, in ulcerative colitis. Abbvie is also interested in NX-13’s potential in Crohn’s disease.

Dive Insight:

AbbVie has struck a string of acquisitions as it works to bolster its drug pipeline in the wake of copycat competition to its top-seller Humira in the U.S.

Unlike recent multibillion dollar deals for Cerevel Therapeutics and ImmunoGen, the planned buyout of Landos is small. But it’s in keeping with recent trends favoring developers of new drugs for immune conditions.

New mechanisms of action and strong clinical trial results have attracted large pharmaceutical companies such as Roche, which paid $7.1 billion to acquire an inflammatory bowl disease drug. Sanofi and Merck & Co. have also inked major deals for IBD treatments, while Takeda spent billions on a promising psoriasis medicine. Startups pursuing immune disease research are attracting investor attention, too. Just last week, Mirador Therapeutics launched with the year’s largest private funding round.

Landos gives AbbVie an experimental IBD drug that works in a different way than those acquired or licensed by Roche, Sanofi and Merck. The company’s candidate, which showed some positive signs in early-stage testing, targets a cellular pathway known as NLRX1. A Phase 2 study, dubbed NEXUS, is currently enrolling participants in the U.S. and Europe.

Backed by Xontogeny, the biotech launched in 2017 and later raised $100 million in an initial public offering that valued shares at $16 apiece. Shares have declined since and were worth $8 each before market open Monday, when they rose to trade above $21.

AbbVie already sells two blockbuster drugs that can treat types of IBD: Rinvoq, approved for ulcerative colitis and Crohn’s, and Skyrizi, which is only cleared for ulcerative colitis. Rinvoq has had safety concerns and currently carries a black box warning.

The Landos deal is expected to close in the second quarter.

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter.

Advertisement

Recommended Stories

  • Forget Nvidia, These Unstoppable Stocks Are Better Buys

    These stocks have tremendous potential, and it doesn't depend on the growth prospects for artificial intelligence.

  • 1 Unstoppable Pharmaceutical Stock Investors Shouldn't Sleep On

    Eli Lilly may be on the verge of another breakthrough, thanks to its hit GLP-1 medications.

  • FDA Green Lights Pfizer's Gene Therapy For Rare Bleeding Disorder Hemophilia

    Friday, the FDA approved Pfizer Inc’s (NYSE:PFE) Beqvez (fidanacogene elaparvovec-dzkt) for moderate to severe hemophilia B in adult patients who currently use factor IX (FIX) prophylaxis therapy or have current or historical life-threatening hemorrhage, or have repeated, serious spontaneous bleeding episodes, and do not have neutralizing antibodies to adeno-associated virus serotype Rh74var capsid. Beqvez is a one-time treatment designed to enable hemophilia B patients to produce FIX themselves

  • Pfizer Wins FDA Approval For $3.5 Million Gene Therapy, Rivaling CSL, Uniqure

    The FDA approved Pfizer's hemophilia gene therapy on Friday. But Pfizer stock only inched ahead on the approval early Friday.

  • The Cream Of The Crop: 5 Biotechs That Outrank Most Stocks

    The top five biotech stocks today have several commonalities. Among them are strong ratings. Some show promising charts and are Tech Leaders.

  • Should You Buy Moderna Before May 12?

    This ambitious biotech aims to launch 15 products over the coming five years.

  • Top 20 biopharma kick off 9.6% market cap surge in Q1 2024 amid Medicare price talks

    Some companies, however, reported a market capitalisation decline, including Gilead Sciences and Roche.

  • Worried About Assisted Living Costs? Here Are Your Options

    Long-term care in residential facilities like nursing homes is a financial challenge for many. When dealing with a loved one who is disabled, elderly or ill, families often try every other kind of long-term care facility first. Because nursing homes … Continue reading → The post Nursing Home Costs: How You Can Cover Them appeared first on SmartAsset Blog.

  • Gilead (GILD) Q1 Loss Narrower Than Expected, Sales Beat

    Gilead (GILD) reports narrower-than-expected loss in the first quarter. Its sales beat estimates on higher HIV, Oncology and Liver Disease sales.

  • Pfizer Receives FDA Approval for Bleeding Disorder Treatment

    Pfizer has received approval from the Food and Drug Administration for a rare genetic bleeding disorder treatment—the drug-maker’s first gene therapy to be approved in the U.S. The treatment, Beqvez, is for adults with moderate to severe hemophilia B—a disorder that prevents normal blood clotting—and will be available by prescription to eligible patients this quarter, according to the company. “Many people with hemophilia B struggle with the commitment and lifestyle disruption of regular FIX infusions, as well as spontaneous bleeding episodes, which can lead to painful joint damage and mobility issues,” said Adam Cuker, director of University of Pennsylvania’s Comprehensive Hemophilia and Thrombosis Program.